161 related articles for article (PubMed ID: 19648939)
1. Therapy: Targeted but not trouble-free: efalizumab and PML.
Molloy ES; Calabrese LH
Nat Rev Rheumatol; 2009 Aug; 5(8):418-9. PubMed ID: 19648939
[TBL] [Abstract][Full Text] [Related]
2. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.
Kothary N; Diak IL; Brinker A; Bezabeh S; Avigan M; Dal Pan G
J Am Acad Dermatol; 2011 Sep; 65(3):546-551. PubMed ID: 21514689
[TBL] [Abstract][Full Text] [Related]
3. Efalizumab discontinuation: a practical strategy.
Pugashetti R; Koo J
J Dermatolog Treat; 2009; 20(3):132-6. PubMed ID: 19459081
[TBL] [Abstract][Full Text] [Related]
4. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control.
Schwab N; Ulzheimer JC; Fox RJ; Schneider-Hohendorf T; Kieseier BC; Monoranu CM; Staugaitis SM; Welch W; Jilek S; Du Pasquier RA; Brück W; Toyka KV; Ransohoff RM; Wiendl H
Neurology; 2012 Feb; 78(7):458-67; discussion 465. PubMed ID: 22302546
[TBL] [Abstract][Full Text] [Related]
5. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis.
Stoppe M; Thomä E; Liebert UG; Major EO; Hoffmann KT; Claßen J; Then Bergh F
J Neurol; 2014 May; 261(5):1021-4. PubMed ID: 24638202
[No Abstract] [Full Text] [Related]
6. Immunosuppressive therapy in dermatology and PML.
Sterry W; Bagot M; Ferrandiz C; Kragballe K; Papp K; Stingl G
J Dtsch Dermatol Ges; 2009 Jan; 7(1):5. PubMed ID: 19138293
[No Abstract] [Full Text] [Related]
7. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Carson KR; Focosi D; Major EO; Petrini M; Richey EA; West DP; Bennett CL
Lancet Oncol; 2009 Aug; 10(8):816-24. PubMed ID: 19647202
[TBL] [Abstract][Full Text] [Related]
9. Patient fatalities potentially associated with efalizumab use.
Sobell JM; Weinberg JM
J Drugs Dermatol; 2009 Mar; 8(3):215. PubMed ID: 19271366
[No Abstract] [Full Text] [Related]
10. Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab.
Gadzia J; Turner J
J Drugs Dermatol; 2010 Aug; 9(8):1005-9. PubMed ID: 20684152
[TBL] [Abstract][Full Text] [Related]
11. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies.
Tavazzi E; Ferrante P; Khalili K
Clin Microbiol Infect; 2011 Dec; 17(12):1776-80. PubMed ID: 22082208
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies and progressive multifocal leukoencephalopathy.
Berger JR; Houff SA; Major EO
MAbs; 2009; 1(6):583-9. PubMed ID: 20073129
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of 72 patients on prior efalizumab subsequent to the time of voluntary market withdrawal in 2009.
Prater EF; Day A; Patel M; Menter A
J Drugs Dermatol; 2014 Jun; 13(6):712-8. PubMed ID: 24918562
[TBL] [Abstract][Full Text] [Related]
14. Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments.
Di Lernia V
Int J Dermatol; 2010 Jun; 49(6):631-5. PubMed ID: 20618466
[TBL] [Abstract][Full Text] [Related]
15. Assessing long-term drug safety: lessons (re) learned from raptiva.
Seminara NM; Gelfand JM
Semin Cutan Med Surg; 2010 Mar; 29(1):16-9. PubMed ID: 20430303
[TBL] [Abstract][Full Text] [Related]
16. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents.
Piccinni C; Sacripanti C; Poluzzi E; Motola D; Magro L; Moretti U; Conforti A; Montanaro N
Eur J Clin Pharmacol; 2010 Feb; 66(2):199-206. PubMed ID: 19838692
[TBL] [Abstract][Full Text] [Related]
17. [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].
Hartung HP; Warnke C; Hohlfeld R; Kieseier BC
Nervenarzt; 2009 Oct; 80(10):1143-4, 1146-8, 1150-3. PubMed ID: 19357826
[TBL] [Abstract][Full Text] [Related]
18. Lessons from the clinic: a case of natalizumab-associated PML.
Clifford DB
Neurology; 2011 Feb; 76(6):574. PubMed ID: 21300972
[No Abstract] [Full Text] [Related]
19. Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists.
Korman BD; Tyler KL; Korman NJ
Arch Dermatol; 2009 Aug; 145(8):937-42. PubMed ID: 19687432
[No Abstract] [Full Text] [Related]
20. PML risk and natalizumab: more questions than answers.
Ransohoff RM
Lancet Neurol; 2010 Mar; 9(3):231-3. PubMed ID: 20117056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
